215 lines
61 KiB
HTML
215 lines
61 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||
<meta charset="utf-8"/>
|
||
<meta content="pandoc" name="generator"/>
|
||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||
<title>17 January, 2022</title>
|
||
<style type="text/css">
|
||
code{white-space: pre-wrap;}
|
||
span.smallcaps{font-variant: small-caps;}
|
||
span.underline{text-decoration: underline;}
|
||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||
</style>
|
||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||
<body>
|
||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||
<ul>
|
||
<li><a href="#from-preprints">From Preprints</a></li>
|
||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||
<ul>
|
||
<li><strong>The Indonesian Government’s Defense Economic Program for the Small Business Economy During the Covid-19 Pandemic for Economic Resilience</strong> -
|
||
<div>
|
||
The Indonesian government always pays attention and focuses on the context of economic recovery during the Covid-19 Pandemic to MSMEs so that they are able to rise from adversity and be able to reabsorb workers who have lost their jobs during the COVID-19 pandemic. Many businesses, especially Micro, Small and Medium Enterprises, went bankrupt and closed their businesses due to demand from consumers who fell free. This study uses the strategy theory of Lykke, 1989 which includes 3 (three) aspects of Ends, Ways and Means, with descriptive qualitative methods. various strategies. This paper aims to discuss the importance of the Government’s Strategy in helping Micro, Small and Medium Enterprises during the COVID-19 pandemic in order to survive and continue to increase their business in supporting Indonesia’s economic resilience. The results achieved are the need to improve strategies on Ways, including the right strategy starting with a regulatory framework and incentives in the form of policies in legislation, government regulations that are comprehensive and sustainable in helping the MSME sector to survive and get out of difficulties during the Covid pandemic. -19 so that it can support the economic resilience of the Indonesian people and nation.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/dbvmq/" target="_blank">The Indonesian Government’s Defense Economic Program for the Small Business Economy During the Covid-19 Pandemic for Economic Resilience</a>
|
||
</div></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>One wave or another in the pandemic: Psychological well-being during the third COVID-19 wave</strong> -
|
||
<div>
|
||
After a year from the emergence of the Coronavirus disease (COVID-19) on February 2020, between March and May 2021 Italy faced its third wave of infections. Previous studies have shown that in the first phases of the pandemic certain factors had a protective role against distress. However, as the months in the pandemic went by, people’s feelings and experiences significantly changed and little is known regarding the role of possible protective variables after prolonged pandemic situations. In the present study we aimed to investigate the impact of several behavioral variables on individuals’ mental states and emotions experienced during the third COVID-19 wave in Italy. 454 Italian adults were asked questions regarding the intensity of mental states and emotions experienced, the perceived usefulness of lockdown, the feeling of living a normal life, and the coping strategies implemented to face the pandemic. Using a data driven approach, we calculated the best model on the participation of each factor in explaining participants’ emotions and mental states. Our findings indicate that the presence of acceptance attitudes toward restrictive measures and the implementation of recreational activities helped participants face a prolonged pandemic with positive emotions.
|
||
</div></li>
|
||
</ul>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/tbcx7/" target="_blank">One wave or another in the pandemic: Psychological well-being during the third COVID-19 wave</a>
|
||
</div>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The statistical analysis of daily data associated with different parameters of the New Coronavirus COVID-19 pandemic in Georgia and their monthly interval prediction from September 1, 2021 to December 31, 2021</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The lockdown introduced in Georgia on November 28, 2020 contributed to positive trends in the spread of COVID-19 until February - the first half of March 2021. Then, in April-May 2021, the epidemiological situation worsened significantly, and from June to the end of December COVID - situation in Georgia was very difficult. In this work results of the next statistical analysis of the daily data associated with New Coronavirus COVID-19 infection of confirmed (C), recovered (R), deaths (D) and infection rate (I) cases of the population of Georgia in the period from September 01, 2021 to December 31, 2021 are presented. It also presents the results of the analysis of monthly forecasting of the values of C, D and I. As earlier, the information was regularly sent to the National Center for Disease Control & Public Health of Georgia and posted on the Facebook page https://www.facebook.com/Avtandil1948/. The analysis of data is carried out with the use of the standard statistical analysis methods of random events and methods of mathematical statistics for the non-accidental time-series of observations. In particular, the following results were obtained. Georgia9s ranking in the world for Covid-19 monthly mean values of infection and deaths cases in investigation period (per 1 million population) was determined. Among 157 countries with population ≥ 1 million inhabitants in October 2021 Georgia was in the 4 place on new infection cases, and in September - in the 1 place on death. Georgia took the best place in terms of confirmed cases of diseases (thirteenth) in December, and in mortality (fifth) - in October. A comparison between the daily mortality from Covid-19 in Georgia from September 01, 2021 to December 31, 2021with the average daily mortality rate in 2015-2019 shows, that the largest share value of D from mean death in 2015-2019 was 76.8 % (September 03, 2021), the smallest 18.7 % (November 10, 2021). As in previous work [9,10] the statistical analysis of the daily and decade data associated with coronavirus COVID-19 pandemic of confirmed, recovered, deaths cases and infection rate of the population of Georgia are carried out. Maximum daily values of investigation parameters are following: C = 6024 (November 3, 2021), R = 6017 (November 15, 2021), D = 86 (September 3, 2021), I = 12.04 % (November 24, 2021). Maximum mean decade values of investigation parameters are following: C = 4757 (1 Decade of November 2021), R = 4427 (3 Decade of November 2021), D = 76 (2 Decade of November 2021), I = 10.55 % (1 Decade of November 2021). It was found that as in spring and summer 2021 [9,10], from September to December 2021 the regression equations for the time variability of the daily values of C, R, D and I have the form of a tenth order polynomial. Mean values of speed of change of confirmed -V(C), recovered - V(R), deaths - V(D) and infection rate V(I) coronavirus-related cases in different decades of months for the indicated period of time were determined. Maximum mean decade values of investigation parameters are following: V(C) = +139 cases/day (1 Decade of October 2021), V(R) = +124 cases/day (3 Decade of October 2021), V(D) = +1.7 cases/day (3 Decade of October 2021), V(I) = + 0.20 %/ day (1 decades of October 2021). Cross-correlations analysis between confirmed COVID-19 cases with recovered and deaths cases shows, that from September 1, 2021 to November 30, 2021 the maximum effect of recovery is observed on 12 and 14 days after infection (CR=0.77 and 0.78 respectively), and deaths</p></div></li>
|
||
<li>after 7, 9, 11, 13 and 14 days (0.70≤CR≤0.72); from October 1, 2021 to December 31, 2021 - the maximum effect of recovery is observed on 14 days after infection (RC=0.71), and deaths - after 9 days (CR=0.43). In Georgia from September 1, 2021 to November 30, 2021 the duration of the impact of the delta variant of the coronavirus on people (recovery, mortality) could be up to 28 and 35 days respectively; from October 1, 2021 to December 31, 2021 - up to 21 and 29 days respectively. Comparison of daily real and calculated monthly predictions data of C, D and I in Georgia are carried out. It was found that in investigation period of time daily and mean monthly real values of C, D and I practically fall into the 67% - 99.99% confidence interval of these predicted values. Traditionally, the comparison of data about C and D in Georgia (GEO) with similar data in Armenia (ARM), Azerbaijan (AZE), Russia (RUS), Turkey (TUR) and in the World (WRL) is also carried out.
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.16.22269373v1" target="_blank">The statistical analysis of daily data associated with different parameters of the New Coronavirus COVID-19 pandemic in Georgia and their monthly interval prediction from September 1, 2021 to December 31, 2021</a>
|
||
</div></li>
|
||
<li><strong>Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: Background incidence rates are critical in pharmacovigilance to facilitate identification of vaccine safety signals. We estimated background incidence rates of nine adverse events of special interest related to COVID-19 vaccines in Ontario, Canada. Methods: We conducted a population-based retrospective observational study using linked health administrative databases for hospitalizations and emergency department visits among Ontario residents. We estimated incidence rates of Bells palsy, idiopathic thrombocytopenia, febrile convulsions, acute disseminated encephalomyelitis, myocarditis, pericarditis, Kawasaki disease, Guillain-Barre syndrome, and transverse myelitis during five pre-pandemic years (2015-2019) and 2020. Results: The average annual population was 14 million across all age groups with 51% female. The pre-pandemic mean annual rates per 100,000 population during 2015-2019 were 43.9 for idiopathic thrombocytopenia, 27.8 for Bells palsy, 25.0 for febrile convulsions, 22.8 for acute disseminated encephalomyelitis, 11.3 for myocarditis/pericarditis, 8.6 for pericarditis, 2.9 for myocarditis, 1.9 for Guillain-Barre syndrome, 1.7 for transverse myelitis, and 1.6 for Kawasaki disease. Females had higher rates of acute disseminated encephalomyelitis and transverse myelitis while males had higher rates of myocarditis, pericarditis, and Guillain-Barre syndrome. Bells palsy, acute disseminated encephalomyelitis, and Guillain-Barre syndrome increased with age. The mean rates of myocarditis and/or pericarditis increased with age up to 79 years; males had higher rates than females: from 12-59 years for myocarditis and 12 years and older for pericarditis. Febrile convulsions and Kawasaki disease were predominantly childhood diseases and generally decreased with age. Conclusions: Our estimated background rates will permit estimating numbers of expected events for these conditions and facilitate detection of potential safety signals following COVID-19 vaccination.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.12.22269169v1" target="_blank">Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance</a>
|
||
</div></li>
|
||
<li><strong>Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 04 November 2021 that provide effectiveness data on mRNA vaccines approved/licensed in the United States and identified eight eligible studies which evaluated vaccine effectiveness in older adults. There is evidence of a decline in vaccine effectiveness against both SARS-CoV-2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that vaccine effectiveness diminishes in older adults, which supports the current recommendation for a booster dose in this population.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.15.22269364v1" target="_blank">Waning Effectiveness of SARS-CoV-2 mRNA Vaccines in Older Adults: A Rapid Review</a>
|
||
</div></li>
|
||
<li><strong>Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
BACKGROUND: We aimed to assess the efficacy of 3 COVID-19 vaccines in a population of health care workers at a tertiary cancer center in Amman, Jordan. METHODS: We evaluated the records of 2855 employees who were fully vaccinated with 1 of 3 different vaccines and those of 140 employees who were not vaccinated. We measured the number of SARS-CoV-2 infections that occurred at least 14 days after the second vaccine dose. RESULTS The 100-day cumulative incidence of PCR-confirmed SARS-CoV-2 infections was 19.3% +/- 3.3% for unvaccinated employees and 1.7% +/- 0.27% for fully vaccinated employees. The 100-day cumulative infection rates were 0.7% +/- 0.22% in BNT162b2 vaccine recipients (n = 1714), 3.6% +/- 0.77% in BBIBP-CorV recipients (n = 680), and 2.3% +/- 0.73% in ChAdOx1 recipients (n = 456). We used Cox regression analyses to compare the risks of SARS-CoV-2 infection among the different vaccine recipient groups and found a significantly higher infection risk in BBIBP-CorV (hazard ratio [HR] = 2.9 +/- 0.31) and ChAdOx1 recipients (HR = 3.0 +/- 0.41) compared to BNT162b2 recipients (P = .00039 and .0074, respectively). Vaccinated employees who had no previously confirmed SARS-CoV-2 infections were at a markedly higher risk for breakthrough infections than those who experienced prior infections (HR = 5.7 +/- 0.73, P = .0178). CONCLUSIONS: Our study offers a real-world example of differential vaccine efficacy among a high-risk population during a national outbreak. We also show the important synergism between a previous SARS-CoV-2 infection and vaccination.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.15.22269356v1" target="_blank">Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan</a>
|
||
</div></li>
|
||
<li><strong>Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Evaluation of vaccine effectiveness over time against severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection or coronavirus disease 2019 (COVID-19) is important. Evidence on effectiveness over time for the CoronaVac vaccine is lacking despite its widespread use globally. In Malaysia, a diverse set-up of COVID-19 vaccines was rolled out nationwide, and the waning of vaccine protection is a concern. We aimed to investigate and compare waning vaccine effectiveness against COVID-19 infections, COVID-19 related ICU admission and COVID-19 related deaths for BNT162b2 and CoronaVac vaccines. In this observational study, we consolidated nationally representative data on COVID-19 vaccination and patients′ outcomes. Data on all confirmed COVID-19 cases from 1 to 30 September 2021 were used to compare vaccine effectiveness between the ′early′ group (fully vaccinated in April to June 2021) and the ′late′ group (fully vaccinated in Jul to Aug 2021). We used a negative binomial regression model to estimate vaccine effectiveness against COVID-19 infections for both ′early′ and ′late′ groups, by comparing the rates of infection for individuals vaccinated in the two different periods relative to the unvaccinated. Among confirmed COVID-19 cases, we used logistic regression to estimate and compare vaccine effectiveness against ICU admission and deaths between the two different periods. For BNT162b2, vaccine effectiveness against COVID-19 infections declined from 90.8% (95% CI 89.4, 92.0) in the late group to 79.1% (95% CI 75.8, 81.9) in the late group. Vaccine effectiveness for BNT162b2 against ICU admission and deaths were comparable between the two different periods. For CoronaVac, vaccine effectiveness waned against COVID-19 infections from 74.4% in the late group (95% CI 209 70.4, 77.8) to 30.0% (95% CI 18.4, 39.9) in the early group. It also declined significantly against ICU admission, dropping from 56.1% (95% CI 51.4, 60.2) to 29.9% (95% CI 13.9, 43.0). For deaths, however, CoronaVac′s effectiveness did not wane after three to five months of full vaccination. Vaccine effectiveness against COVID-19 infections waned after three to five months of full vaccination for both BNT162b2 and CoronaVac in Malaysia. Additionally, for CoronaVac, protection against ICU admission declined as well. Evidence on vaccine effectiveness over time informs evolving policy decisions on vaccination.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.15.22269326v1" target="_blank">Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study</a>
|
||
</div></li>
|
||
<li><strong>Using Mobile Phone-based Text Message to Recruit Representative Samples: Assessment of a Cross-Sectional Survey about the COVID-19 Vaccine Hesitation.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: Limited research has examined mobile phone-based platforms for survey recruitment, especially during the COVID-19 pandemic in Brazil. Our objective was to investigate the feasibility and representativeness of mobile phone-based advertisement during a preliminary study about COVID-19 vaccine hesitation in Brazil. Moreover, we evaluate whether the older population can be reached through mobile phone-based platforms of the survey. Methods: We conducted a study in December 2021 based on a preliminary survey about the COVID-19 vaccine hesitation in Assis, Brazil, Sao Paulo state. From a list of the adult population hesitant for the second dose of the COVID-19 vaccine, we sent a mobile phone- based advertisement inviting the participants to answer the survey for one week. The respondent9s data were collected in a Google form platform. The comparison between the target population and the respondents was made using the Chi-squared test and the Welch9s test, using a P-value of .05 as significative. Results: The response rate was 9.99% after one week. The mean age of the respondent group was 33.97 (SD 14.99) and 35.05 (SD 14.19) of the population, with a P-value of .192 and a Cohen9s d coefficient of 0.0754, corresponding to a small effect size between groups. We demonstrate that the mobile phone-based survey is a feasible and representative strategy during the pandemics in Brazil. Moreover, the older population respondent was representative. Conclusion: We achieved a representative sample of respondents using the mobile phone-based survey in Brazil. Furthermore, it was representative in all sociodemographic and health characteristics assessed. Finally, these findings suggest the method is a highly feasible and economical means of recruiting for survey research.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.15.22269259v1" target="_blank">Using Mobile Phone-based Text Message to Recruit Representative Samples: Assessment of a Cross-Sectional Survey about the COVID-19 Vaccine Hesitation.</a>
|
||
</div></li>
|
||
<li><strong>Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Immune dysregulation in individuals with Down syndrome (DS) leads to an increased risk for hospitalization and death due to COVID-19 and may impair the generation of protective immunity after vaccine administration. The cellular and humoral responses of 55 DS patients who received a complete SARS-CoV-2 vaccination regime at one to three (V1) and six (V2) months were characterised. SARS-CoV-2-reactive CD4+ and CD8+ T lymphocytes with a predominant Th1 phenotype were observed at V1, and increased at V2. Likewise, a sustained increase of SARS-CoV-2-specific circulating Tfh (cTfh) cells was observed one to three months after vaccine administration. Specific IgG antibodies against SARS- CoV-2 S protein were detected in 96% and 98% of subjects at V1 and V2, respectively, though IgG titers decreased significantly between both timepoints.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.14.22269303v1" target="_blank">Development of an effective immune response in adults with Down Syndrome after SARS-CoV-2 vaccination</a>
|
||
</div></li>
|
||
<li><strong>Associations Between Physical Activity, Affect Regulation Difficulties, and Mental Health Among Canadian Adolescents at Two Different Points of the COVID-19 Pandemic</strong> -
|
||
<div>
|
||
Although physical activity declined with social distancing measures and stay-at-home orders during the COVID-19 pandemic, youth who engaged in more physical activity experienced fewer mental health problems. If and how physical activity maintained its protective role throughout the ongoing pandemic remains unclear. This study models associations between three types of physical activity (indoor, outdoor, with parents), affect regulation, and anxious and depressive symptoms in two adolescent samples (W1: Summer 2020; W2: Winter 2020/21).
|
||
</div>
|
||
<div class="article-link article-html- link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/y2b4k/" target="_blank">Associations Between Physical Activity, Affect Regulation Difficulties, and Mental Health Among Canadian Adolescents at Two Different Points of the COVID-19 Pandemic</a>
|
||
</div></li>
|
||
<li><strong>Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Emergence of the SARS-CoV-2 variant-of-concern (VOC) B.1.1.529 (Omicron) in late 2021 has raised alarm among scientific and health care communities due to a surprisingly large number of mutations in its spike protein. Public health surveillance indicates that the Omicron variant is significantly more contagious than the previously dominant VOC, B.1.617.2 (Delta). Several early reports demonstrated that Omicron exhibits a higher degree (~10-30-fold) of escape from antibody neutralization compared to earlier lineage variants. Therefore, it is critical to determine how well the second line of adaptive immunity, T cell memory, performs against Omicron in people following COVID-19 infection and/or vaccination. To that purpose, we analyzed a cohort (n=345 subjects) of two- or three- dose messenger RNA (mRNA) vaccine recipients and COVID-19 post infection subjects (including those receiving 2 doses of mRNA vaccine after infection), recruited to the CDC-sponsored AZ HEROES research study, alongside 32 pre-pandemic control samples. We report that T cell responses against Omicron spike peptides were largely preserved in all cohorts with established immune memory. IFN-gamma producing T cell responses remained equivalent to the response against the ancestral strain (WA1/2020), with some (<20%) loss in IL-2 single- or IL-2+IFN-gamma+ poly-functional responses. Three-dose vaccinated participants had similar responses to Omicron relative to convalescent or convalescent plus two-dose vaccinated groups and exhibited responses significantly higher than those receiving two mRNA vaccine doses. These results provide further evidence that a three-dose vaccine regimen benefits the induction of optimal functional T cell immune memory.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.16.22269361v1" target="_blank">Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant</a>
|
||
</div></li>
|
||
<li><strong>A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: Accurate rapid antibody detection kits requiring minimum infrastructure are beneficial in detecting post-vaccination antibodies in large populations. ChAdOx1-nCOV (COVISHIELD) and BBV-152 (Covaxin) vaccines are primarily used in India. Methods: In this single-centre prospective study, performance of Meril ABFind was investigated by comparing with Abbott SARS-CoV-2 IgG II Quant (Abbott Quant), GenScript cPass SARS-CoV-2 neutralization antibody detection kit (GenScript cPass), and COVID Kawach MERILISA (MERILISA) in 62 vaccinated health care workers (HCW) and 40 pre-pandemic samples. Results: In the vaccinated subjects, Meril ABFind kit displayed high sensitivity of 93.3% (CI, 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) in comparison to Abbott Quant, MERILISA, and GenScript cPass respectively. The results of the Meril ABFind in the COVISHIELD-vaccinated group were excellent with 100% sensitivity in comparison to the other three kits. In the Covaxin-vaccinated group, Meril ABFind displayed sensitivity ranging from 80% to 88.9%. In control samples, there were no false positives detected by Meril ABFind, while Abbott Quant, MERILISA, and GenScript cPass reported 2.5%, 10.0%, and 12.5% false positives, respectively. In the pre- pandemic controls, specificity of Meril ABFind was 100%, Abbott Quant 97.5%, MERILISA 90%, and GenScript cPass 87.5%. Conclusion: The Meril ABFind kit demonstrated satisfactory performance when compared with the three commercially available kits and was the only kit without false positives in the pre-pandemic samples. This makes it a viable option for rapid diagnosis of post vaccination antibodies.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.15.22269231v1" target="_blank">A prospective, single- center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19</a>
|
||
</div></li>
|
||
<li><strong>On serendipity and innovations in public health</strong> -
|
||
<div>
|
||
I briefly discuss about serendipity in the cases of penicillin discovery and Covid-19 vaccine research.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/ey7k3/" target="_blank">On serendipity and innovations in public health</a>
|
||
</div></li>
|
||
<li><strong>The impact of the COVID-19 pandemic on hospital services for patients with cardiac diseases: a scoping review</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: The repercussions of the COVID-19 pandemic concern care in many clinical areas, including cardiology. We aim to assess the impact of the COVID-19 pandemic on hospital care for cardiac patients. Methods: Scoping review. Performance indicators were extracted and collated to inform on changes in the use of health services and care provided during January - June 2020. Results: Database searches yielded 6277 articles, of which 838 articles met the inclusion criteria during initial screening. After full-text screening, 94 articles were considered for data extraction. In total, 1637 indicators were retrieved, showing large variation in the indicators and their definitions. Most of the indicators that provided information on changes in number of admissions (n=118, 88%) signalled a decrease in admissions; 88% (n=15) of the indicators showed patients delayed presentation and 40% (n=54) showed patients in a worse clinical condition. A reduction in diagnostic and treatment procedures was signalled by 95% (n=18) and 81% (n=64) of the indicators reporting on cardiac procedures, respectively. Length of stay decreased in 58% (n=21) of the indicators and acute coronary syndromes treatment times increased in 61% (n=65) of the indicators. Outpatient activity decreased in 94% (n=17) of the indicators related with outpatient care, whereas telehealth utilization increased in 100% (n=6). Outcomes worsened in 40% (n=35) of the indicators, and mortality rates increased in 52% (n=31). Conclusion: All phases of the hospital cardiac care pathway were affected. This information could support the planning of care during the ongoing pandemic and in future events.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html- link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.12.01.21267100v2" target="_blank">The impact of the COVID-19 pandemic on hospital services for patients with cardiac diseases: a scoping review</a>
|
||
</div></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Can lifestyle factors be the key in deciding the COVID-19 outcome?</strong> -
|
||
<div>
|
||
The COVID-19 recovery rate of 97.3% and the death per million of 345 in India are better than the corresponding values in the USA and most of Europe despite better health infrastructure in these countries. The mean COVID fatality rate of Europe and a few countries in America is seven times that of India. This warrants a systematic study of the factors behind this conspicuous disparity. It is time to study lifestyle and other factors that may be related to recovery with minimal medical intervention or serious complications, leading to belated recovery and sometimes mortality. Obesity and excessive consumption of soft drinks, red meat and processed food may have a role to play in the European and American countries. On the other hand, the use of turmeric, black pepper, ginger in daily cooking, consumption of Indian gooseberry, Tulasi, different decoctions (Kashaya) and practice of various immune-boosting breathing exercises including yoga might have had a role in India. A detailed study involving a sizable number of cases of recovery and death in India, USA and some European countries will throw light on these factors behind the significant differences. The results shall provide crucial learning to the world for managing future waves and pandemics.
|
||
</div></li>
|
||
</ul>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/qhupm/" target="_blank">Can lifestyle factors be the key in deciding the COVID-19 outcome?</a>
|
||
</div>
|
||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: MIR 19 ®; Combination Product: Standard COVID-19 therapy<br/><b>Sponsors</b>: National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia; St. Petersburg Research Institute of Vaccines and Sera<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Telemedicine Brief Mindfulness Intervention in Post-COVID-19</strong> - <b>Condition</b>: Post COVID-19<br/><b>Intervention</b>: Other: Mindfulness<br/><b>Sponsors</b>: <br/>
|
||
Fondazione Don Carlo Gnocchi Onlus; Catholic University of the Sacred Heart<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant; Biological: Saline placebo<br/><b>Sponsors</b>: Cinnagen; Vaxine Pty Ltd<br/><b>Active, not recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Therapeutic plasma exchange<br/><b>Sponsor</b>: <br/>
|
||
Centre Hospitalier St Anne<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Favipiravir; Drug: Remdesivir<br/><b>Sponsors</b>: Promomed, LLC; Solyur Pharmaceuticals Group<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: unfractionated Heparin<br/><b>Sponsors</b>: <br/>
|
||
Australian National University; The George Institute; St George Hospital, Australia; St Vincent’s Hospital Melbourne; John Hunter Hospital; Royal North Shore Hospital<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer- BioNTech COVID-19 Vaccine.</strong> - <b>Condition</b>: Covid19 Vaccine<br/><b>Interventions</b>: Biological: PTX-COVID19-B; Biological: Pfizer- BioNTech COVID-19 vaccine; Biological: Placebo<br/><b>Sponsor</b>: Providence Therapeutics Holdings Inc.<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity and Safety Study of a SCB-2019 Vaccine Booster Dose to Adults Who Previously Received Primary Series of Selected COVID-19 Vaccines</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: Candidate vaccine, SCB-2019<br/><b>Sponsor</b>: Clover Biopharmaceuticals AUS Pty Ltd<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Messaging for Vaccination</strong> - <b>Conditions</b>: Vaccination Refusal; COVID-19 Pandemic<br/><b>Interventions</b>: Behavioral: Doctor Videos; Behavioral: Sharing Videos; Behavioral: Sharing Videos (Influencers); Behavioral: Vaccine Ambassador; Behavioral: Video framing; Behavioral: Video order<br/><b>Sponsors</b>: Massachusetts Institute of Technology; Facebook, Inc.; Code3; Stanford University; Harvard University; Yale University; Johns Hopkins University; Massachusetts General Hospital; Ludwig-Maximilians - University of Munich; National Institutes of Health (NIH)<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES.</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Diagnostic Test: Evolution of antibodies titre<br/><b>Sponsor</b>: Cliniques universitaires Saint-Luc- Université Catholique de Louvain<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome</strong> - <b>Condition</b>: COVID-19 Respiratory Infection<br/><b>Interventions</b>: Dietary Supplement: ubiquinol (reduced coenzyme Q10); Other: mountain spa rehabilitation; Diagnostic Test: 2x14 ml of peripheral blood collected in a tube with anticoagulant<br/><b>Sponsors</b>: Comenius University; Sanatórium of Dr. Guhr, n.o.<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect of Dietary Intervation on Endothelial Glycocalyx in COVID-19 Patients.</strong> - <b>Conditions</b>: COVID-19; Endothelial Dysfunction<br/><b>Interventions</b>: <br/>
|
||
Dietary Supplement: Food supplement Endocalyx; Dietary Supplement: Placebo<br/><b>Sponsor</b>: <br/>
|
||
University of Athens<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Public Support for COVID-19 Test Allocation</strong> - <b>Conditions</b>: Health Equity; COVID-19<br/><b>Interventions</b>: Behavioral: First Come, First Served; Behavioral: Random; Behavioral: Disadvantaged Priority & Random<br/><b>Sponsor</b>: University of Pennsylvania<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Olokizumab; Drug: Standard therapy<br/><b>Sponsors</b>: R-Pharm; Federal Budget Institution of Science “Central Research Institute of Epidemiology” of the Rospotrebnadzor; Group of companies Medsi, JSС<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID in Healthy Adult Volunteers</strong> - <b>Condition</b>: COVID-19 Vaccine<br/><b>Interventions</b>: Drug: EG-COVID-003; Drug: EG-COVID-001<br/><b>Sponsors</b>: EyeGene Inc.; Novotech (Australia) Pty Limited<br/><b>Not yet recruiting</b></p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 M(pro) Explored by QM/MM Simulations</strong> - The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2, SARS-CoV-2, shows the need for effective antiviral treatments. Here, we present a simulation study of the inhibition of the SARS-CoV-2 main protease (M^(pro)), a cysteine hydrolase essential for the life cycle of the virus. The free energy landscape for the mechanism of the inhibition process is explored by QM/MM umbrella sampling and free energy perturbation simulations at the M06-2X/MM level of theory for two…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Validation of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2 Infection</strong> - CONCLUSIONS: RT-PCR assays conducted on a stored saliva sample achieved similar performance to those on NP swabs, and this may provide a very effective tool for population screening and diagnosis. Collection of saliva in a stabilizing solution makes the test more convenient and widely available; furthermore, the denaturing properties of the solution reduce the infective risks belonging to sample manipulation.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sustained generation of peroxide from the air by carbon nano onion under visible light to combat RNA virus</strong> - Carbon nano onion (CNO) from dried grass has been synthesized by carbonization in the size range, 20 to 100 nm. This shows catalytic property to transform aerial oxygen under visible light to generate reactive oxygen species (ROS). A concept has been presented herein to show that this CNO even under room light generates hydrogen peroxide which inhibits WSN influenza virus (H1N1). The advantage of introducing CNO, synthesized from a cheap source to cater to the global need, is to sterilize…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Local practices and production confer resilience to rural Pacific food systems during the COVID-19 pandemic</strong> - Resilience of food systems is key to ensuring food security through crisis. The COVID-19 pandemic presents an unprecedented shock that reveals varying levels of resilience of increasingly interconnected food systems across the globe. We contribute to the ongoing debate about whether increased connectivity reduces or enhances resilience in the context of rural Pacific food systems, while examining how communities have adapted to the global shocks associated with the pandemic to ensure food…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potential of phytocompounds from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structural and molecular insights</strong> - By 24th Sep. 2021, there are more than 229 million COVID-19 cases worldwide, the researchers are tirelessly working to discover and develop an efficient drug molecule against this devastative viral infection. This study aims to evaluate the inhibitory efficiency of the organic acids and phenolic compounds present in Brassica oleracea (Tronchuda Cabbage) against spike glycoprotein in SARS-CoV-2. Thirty-seven phytocompounds are screened on the basis of their molecular weight (<500 g/mol) and 14…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study</strong> - The novel coronavirus disease (COVID-19) has spread throughout the globe, affecting millions of people. The World Health Organization (WHO) has declared this infectious disease a pandemic. At present, several clinical trials are going on to identify possible drugs for treating this infection. SARS-CoV-2 M^(pro) is one of the most critical drug targets for the blockage of viral replication. The aim of this study was to identify potential natural anthraquinones that could bind to the active site…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Xuanfei Baidu Decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathway</strong> - The pathogenic hyper-inflammatory response has been revealed as the major cause of the severity and death of the Corona Virus Disease 2019 (COVID-19). Xuanfei Baidu Decoction (XFBD) as one of the “three medicines and three prescriptions” for the clinically effective treatment of COVID-19 in China, shows unique advantages in the control of symptomatic transition from moderate to severe disease states. However, the roles of XFBD to against hyper-inflammatory response and its mechanism remain…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>K63 ubiquitination in immune signaling</strong> - Ubc13-catalyzed K63 ubiquitination is a major control point for immune signaling. Recent evidence has shown that the control of multiple immune functions, including chronic inflammation, pathogen responses, lymphocyte activation, and regulatory signaling, is altered by K63 ubiquitination. In this review, we detail the novel cellular sensors that are dependent on K63 ubiquitination for their function in the immune signaling network. Many pathogens, including severe acute respiratory syndrome…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle</strong> - The advent and persistence of the Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2)-induced Coronavirus Disease (COVID-19) pandemic since December 2019 has created the largest public health emergency in over a century. Despite the administration of multiple vaccines across the globe, there continues to be a lack of approved efficacious non-prophylactic interventions for the disease. Flavonoids are a class of phytochemicals with historically established antiviral, anti-inflammatory…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Inhibition of RNA Viruses by Amaryllidaceae Alkaloids: Opportunities for the Development of Broad-Spectrum Anti- Coronavirus Drugs</strong> - The global COVID-19 pandemic has claimed the lives of millions and disrupted nearly every aspect of human society. Currently, vaccines remain the only widely available medical means to address the cause of the pandemic, the SARS-CoV-2 virus. Unfortunately, current scientific consensus deems the emergence of vaccine-resistant SARS-CoV-2 variants highly likely. In this context, the design and development of broad-spectrum, small-molecule based antiviral drugs has been described as a potentially…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Comparative investigation of toxicity induced by UV-A and UV-C radiation using Allium test</strong> - Organisms are increasingly exposed to ultraviolet (UV) rays of sunlight, due to the thinning of the ozone layer and its widespread use in sterilization processes, especially against the SARS-CoV-2 virus. The present study was conducted with the purpose of evaluating the damages of UV-A and UV-C radiations in Allium cepa L. roots. The effects of two different types of UV on some physiological, biochemical, cytogenotoxic, and anatomical parameters were investigated in a multifaceted study. Three…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy</strong> - The current COVID-19 global pandemic poses immense challenges to global health, largely due to the difficulty to detect infection in the early stages of the disease, as well as the current lack of effective antiviral therapy. Research and understanding of the human immune system can provide important theoretical and technical support for the clinical diagnosis and treatment of COVID-19, the clinical implementations of which include immunoassays and immunotherapy, which play a crucial role in the…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19</strong> - Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX-1) in patients with severe coronavirus disease 2019 (COVID-19). The potent anaphylatoxin C5a attracts neutrophils and monocytes to the infection site, causes tissue damage by oxidative radical formation and enzyme releases, and leads to activation of the coagulation system. Results demonstrated that…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Synthesis of low-molecular weight fucoidan derivatives and their binding abilities to SARS-CoV-2 spike proteins</strong> - Fucoidan derivatives 10-13, whose basic sugar chains are composed of repeating α(1,4)-linked l-fucopyranosyl residues with different sulfation patterns, were designed and systematically synthesized. A structure-activity relationship (SAR) study examined competitive inhibition by thirteen fucoidan derivatives against heparin binding to the SARS-CoV-2 spike</li>
|
||
</ul>
|
||
<ol start="19" type="A">
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">protein. The results showed for the first time that 10 exhibited the highest inhibitory activity of the fucoidan derivatives used. The…</li>
|
||
</ol>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2</strong> - SARS-CoV-2 infection of human cells is initiated by the binding of the viral Spike protein to its cell-surface receptor ACE2. We conducted a targeted CRISPRi screen to uncover druggable pathways controlling Spike protein binding to human cells. Here we show that the protein BRD2 is required for ACE2 transcription in human lung epithelial cells and cardiomyocytes, and BRD2 inhibitors currently evaluated in clinical trials potently block endogenous ACE2 expression and SARS-CoV-2 infection of human…</li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>IDENTIFICATION AND ALARM SYSTEM FOR FACIAL CORONA MASK USING CNN BASED IMAGE PROCESSING</strong> - tThe covid-19 epidemic is the world’s largest wake-up call for people to pay attention to their own and society’s health. One thing to keep in mind is that there is a segment of the population that has been exposed to the covid-19 virus and has generated antibodies without developing any significant illnesses and is continuing to be healthy. This indicates that a significant section of the population, even excluding the elderly, lacks the necessary bodily immunity to combat a Viral infection. As terrible as covid-19 is on a global scale, developing personal health standards and preventative measures for any pathogenic virus as a community would have spared many lives. In’this work, a camera is combined with an image processing system to recognise facial masks, which may be improved in a variety of ways. First and foremost, this method is meant to identify masks on a single person’s face. While this method is efficient in identifying someone has a mask, it does not ensure that they will wear it all of the time. The most effective update for this task is to install a camera with a wide field of view so that many individuals can be seen in the frame, and the faces of those who aren’t wearing markings can be identified, as well as the number of people and the timing. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346889253">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ANTIMICROBIAL SANITIZING FORMULATION</strong> - An antimicrobial sanitizing formulation, comprising, i) isopropyl alcohol in the range of 0.1%- 80% w/w, ii) an emollient in the range of 0.1%-15% w/w, iii) hydrogen peroxide in the range of 0.1 0.13% w/w, iv) citric acid in the range of 0.1% to 2.0% w/w, v) silver nitrate in the range of 0.1% to 0.5% w/w, and vi) a fragrance imparting agent in the range of 0.1% to 2.0% w/w. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346888094">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A HEALTH BAND WITH A BIOMETRIC MODULE AND WORKING METHOD THEREOF</strong> - The present invention discloses a health band with a biometric module and method thereof. The assembly includes, but not limited to, a plurality of sensors configured to gather health data associated with a predefined symptom of a medical condition of a user; a memory unit configured to store the data and an interface, which is configured to determine the medical condition using the data;a processing unit configured to execute the application; and a notification facility configured to provide a notification upon receiving from the interface an instruction associated with the notification, wherein the notification is associated with a drug reminder and the like. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346889061">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>RNA 검출 방법</strong> - 본 발명은 RNA의 분석 및 검출 방법에 관한 것이다. 특히, 본 발명은 특히, 본 발명은 짧은 염기서열의 RNA까지 분석이 가능하면서도 높은 민감도 및 정확도로 정량적 검출까지 가능하여 감염증, 암 등 여러 질환의 진단 용도로도 널리 활용될 수 있다. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=KR346026620">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>REUNION OF PHOTOTHERMAL THERAPY WITH MXENE ADSORBED UREMIC TOXINS AND CYTOKINES: A SHILED FOR COVID-19 PATENTS</strong> - The COVID-19 pandemic has created havoc throughout the world. The disease has proved to be more fatalfor patients having comorbidities like diabetics, lungs and kidney infections, etc. In the case of COVID-19 patientsI having kidney injury, the. removal of uremic toxins from the blood is hindered and there is a rapid surge in the levelj of cytokine hormone resulting in the death of the patient in a short interval of time. To resolve this issue,iI; researchers have examined that the immediate removal of these toxins can improve the condition of the patient to a |greater extent. Studies have also found the presence of SARS CoV-2 viral RNAs in the blood of COVID-19patients, which risks their life as well as impacts the blood transfusion process, especially in the case ofasymptomatic patients. Hence it is required to control the surge of cytokines and uremic toxins as well as disinfectthe blood of the patient from the virus. MXenes, having a foam-like porous structure and hydrophilic negativesurface functionalization have greater adsorption efficiency as well as superior photothermal activity. Utilizingthese properties of MXenes, the MXene membranes can be used in the dialyzer that can help in the efficient andBiuick removal of the uremic toxins, cytokines, and other impurities from the blood. Along with this the greaterTJAdsorption efficiency of MXenes to amino acids result in the trapping of the SARS CoV-2 viruses on the surface J)3>f the MXene. Many researchers as well as the WHO have proved the efficient reduction of the viral copy numbersjjvith the increase of temperature. Hence, followed by the trapping of the viruses, the implementation of"Zphotothermal Therapy can result in the inactivation and denaturation of the viruses and their respective viral RNAsBJlby the produced heat. The same process can be repeated several times to get better results. This whole process canr>oQ-esult in impurity-free and infection-free blood, that can be returned back to the body of the patient or can be!— I Sitilized for the blood transfusion process without any risk of infection.IM - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346889224">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>REDUCING AND STOPPING OXYGEN WASTAGE IN HOSPITAL</strong> - In an aspect, the present invention discloses a system (200) for prevention and reduction of oxygen wastage from oxygen mask (202). The system (200) includes the oxygen mask (202) having straps; a tension sensor (204), the tension sensor being sensitive towards tension produced in the straps as the oxygen gets leakage through sides of the mask (202); a processor configured in alignment with the tension sensor (204); and a buzzer (206) in alignment with processor. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346042219">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hung Thanh Phan COVID-19 NEW SOLUTION</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU344983394">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A METHOD TO REVEAL MOTIF PATTERNS OF COVID-19 USING MULTIPLE SEQUENCE ALIGNMENT</strong> - This present invention consists of different levels of computation and work in a pipeline manner i.e., input of one will be output of another and it is sequential process. Input data given in form of nucleotide sequence (DNA) of different COVID-19 patients (1). Using these nucleotide sequence perform mutation if possible and arrange them in a sequential order (2). Arrange number of nucleotide sequences of different patients in row wise and also compute number of characters in each row. (3). Compute frequency of occurrence of character in column wise and create a matrix having 4 rows and maximum sequence length will be the column size (4). Find the character like A, T, C, and G which one has maximum score and similarly find for each column to produce a final sequence (5). - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346039750">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>REUSABILITY OF ANTIMICROBIAL MULTILAYER NANOFIBER MASK WITH HIGH PROTECTIVE</strong> - According to the present Invention, an antimicrobial multi-layer protective mask has a body section including at least first and second fabric layers having random fiber configuration; a middle layer including nanofiber membrane; and third and fourth fabric layers. There are two layers of fabric sandwiched between the nanofiber membrane and the third fabric layer. Fabric layers 1 through 4 each include a synergistic mixture of at least two metal oxide powders that exhibit synergistic antibacterial capabilities, such as the first metal’s mixed-oxidation state oxide and a second metal’s single-oxidation-state oxide. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN346039053">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>用于检测新型冠状病毒的引物、探针及其应用</strong> - 本发明属于医学检测领域，具体涉及用于检测新型冠状病毒的引物、探针及其应用。本发明设计了四组引物探针，采用常用的TaqMan‑MGB探针法对新型冠状病毒进行检测，可用于检测新型冠状病毒野生型、新型冠状病毒变异株、新型冠状病毒B.1.617亚型变异株以及新型冠状病毒B.1.617.2亚型变异株。假病毒测试结果表明，试剂灵敏度可达到500copies/mL。10份健康志愿者和4份常见其他呼吸道病原体检测均没有非特异性扩增，引物探针组合及试剂特异性较好。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN346990286">link</a></p></li>
|
||
</ul>
|
||
|
||
|
||
<script>AOS.init();</script></body></html> |